Physiological regulation of Akt activity and stability.

GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop. Diabetes (2015) 2.07

Insulin-like growth factor 1 alleviates high-fat diet-induced myocardial contractile dysfunction: role of insulin signaling and mitochondrial function. Hypertension (2012) 1.66

Protein kinases and phosphatases in the control of cell fate. Enzyme Res (2011) 1.23

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer (2012) 1.14

Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci (2012) 1.14

Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex. Hum Mol Genet (2012) 1.10

Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance. Diabetologia (2011) 1.03

Apigenin induces apoptosis in human leukemia cells and exhibits anti-leukemic activity in vivo. Mol Cancer Ther (2011) 0.99

Mechanical regulation of glycogen synthase kinase 3β (GSK3β) in mesenchymal stem cells is dependent on Akt protein serine 473 phosphorylation via mTORC2 protein. J Biol Chem (2011) 0.97

Increased carbonylation of the lipid phosphatase PTEN contributes to Akt2 activation in a murine model of early alcohol-induced steatosis. Free Radic Biol Med (2013) 0.97

MicroRNA-141 and microRNA-146b-5p inhibit the prometastatic mesenchymal characteristics through the RNA-binding protein AUF1 targeting the transcription factor ZEB1 and the protein kinase AKT. J Biol Chem (2014) 0.96

Arrest-defective-1 protein (ARD1): tumor suppressor or oncoprotein? Am J Transl Res (2010) 0.95

Receptor-specific mechanisms regulate phosphorylation of AKT at Ser473: role of RICTOR in β1 integrin-mediated cell survival. PLoS One (2012) 0.95

Marine lipopeptide Iturin A inhibits Akt mediated GSK3β and FoxO3a signaling and triggers apoptosis in breast cancer. Sci Rep (2015) 0.91

Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. J Biol Chem (2013) 0.91

Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. Am J Physiol Endocrinol Metab (2013) 0.91

Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. Laryngoscope (2011) 0.91

The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther (2011) 0.89

Propofol-induced changes in neurotrophic signaling in the developing nervous system in vivo. PLoS One (2012) 0.88

Regulation of cardiac hypertrophic signaling by prolyl isomerase Pin1. Circ Res (2013) 0.88

Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases. J Biol Chem (2010) 0.88

Modulation of the Akt pathway reveals a novel link with PERK/eIF2α, which is relevant during hypoxia. PLoS One (2013) 0.88

PHLPP1 gene deletion protects the brain from ischemic injury. J Cereb Blood Flow Metab (2012) 0.88

Triennial Growth Symposium: leucine acts as a nutrient signal to stimulate protein synthesis in neonatal pigs. J Anim Sci (2010) 0.87

Regulation of the microRNA 200b (miRNA-200b) by transcriptional regulators PEA3 and ELK-1 protein affects expression of Pin1 protein to control anoikis. J Biol Chem (2013) 0.87

InterAKTions with FKBPs--mutational and pharmacological exploration. PLoS One (2013) 0.87

Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells. PLoS One (2011) 0.86

Therapeutic Implications of Targeting AKT Signaling in Melanoma. Enzyme Res (2011) 0.85

A purified capsular polysaccharide markedly inhibits inflammatory response during endotoxic shock. Infect Immun (2012) 0.85

Global gene expression changes in human urothelial cells exposed to low-level monomethylarsonous acid. Toxicology (2011) 0.84

Inhibition of hydrogen peroxide signaling by 4-hydroxynonenal due to differential regulation of Akt1 and Akt2 contributes to decreases in cell survival and proliferation in hepatocellular carcinoma cells. Free Radic Biol Med (2012) 0.83

RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition. Oncogene (2015) 0.83

Differential regulatory functions of three classes of phosphatidylinositol and phosphoinositide 3-kinases in autophagy. Autophagy (2015) 0.82

Muscle-specific Pikfyve gene disruption causes glucose intolerance, insulin resistance, adiposity, and hyperinsulinemia but not muscle fiber-type switching. Am J Physiol Endocrinol Metab (2013) 0.82

Evaluation of MicroRNAs Regulating Anoikis Pathways and Its Therapeutic Potential. Biomed Res Int (2015) 0.82

Candidate tumor suppressor B-cell translocation gene 3 impedes neoplastic progression by suppression of AKT. Cell Death Dis (2015) 0.82

SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice. Oncotarget (2015) 0.81

Short term feeding of a high fat diet exerts an additive effect on hepatocellular damage and steatosis in liver-specific PTEN knockout mice. PLoS One (2014) 0.81

Regulatory networks and complex interactions between the insulin and angiotensin II signalling systems: models and implications for hypertension and diabetes. PLoS One (2013) 0.80

A novel functional interplay between Progesterone Receptor-B and PTEN, via AKT, modulates autophagy in breast cancer cells. J Cell Mol Med (2014) 0.80

Resveratrol inhibits β-amyloid-induced neuronal apoptosis via regulation of p53 acetylation in PC12 cells. Mol Med Rep (2014) 0.80

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs (2014) 0.80

SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1. Oncogene (2015) 0.80

Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J Biol Chem (2014) 0.80

Therapeutic ultrasound reverses peripheral ischemia in type 2 diabetic mice through PI3K-Akt-eNOS pathway. Am J Transl Res (2016) 0.79

High force development augments skeletal muscle signalling in resistance exercise modes equalized for time under tension. Pflugers Arch (2014) 0.79

Early Steps of Jaagsiekte Sheep Retrovirus-Mediated Cell Transformation Involve the Interaction between Env and the RALBP1 Cellular Protein. J Virol (2015) 0.79

Deletion of growth hormone receptors in postnatal skeletal muscle of male mice does not alter muscle mass and response to pathological injury. Endocrinology (2013) 0.79

Optimal homeostasis necessitates bistable control. J R Soc Interface (2012) 0.79

Activation of Sirtuin-1 Promotes Renal Fibroblast Activation and Aggravates Renal Fibrogenesis. J Pharmacol Exp Ther (2015) 0.79

Akt blocks the tumor suppressor activity of LKB1 by promoting phosphorylation-dependent nuclear retention through 14-3-3 proteins. Am J Transl Res (2012) 0.79

Heat shock proteins regulate activation-induced proteasomal degradation of the mature phosphorylated form of protein kinase C. J Biol Chem (2013) 0.78

PHLDA3 overexpression in hepatocytes by endoplasmic reticulum stress via IRE1-Xbp1s pathway expedites liver injury. Gut (2015) 0.78

Decreased thioredoxin-1 and increased HSP90 expression in skeletal muscle in subjects with type 2 diabetes or impaired glucose tolerance. Biomed Res Int (2014) 0.78

Fibroblast growth factor 1attenuates 6-hydroxydopamine-induced neurotoxicity: an in vitro and in vivo investigation in experimental models of parkinson's disease. Am J Transl Res (2014) 0.78

Targeting GRP75 improves HSP90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma. PLoS One (2014) 0.78

PR55α Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signaling. Cancer Res (2016) 0.78

Mdm20 stimulates polyQ aggregation via inhibiting autophagy through Akt-Ser473 phosphorylation. PLoS One (2013) 0.78

Phenotype selection reveals coevolution of muscle glycogen and protein and PTEN as a gate keeper for the accretion of muscle mass in adult female mice. PLoS One (2012) 0.78

Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities. Int J Mol Sci (2014) 0.77

Cellular context-mediated Akt dynamics regulates MAP kinase signaling thresholds during angiogenesis. Mol Biol Cell (2015) 0.77

Pretreatment of activated human CD8 T cells with IL-12 leads to enhanced TCR-induced signaling and cytokine production. Mol Immunol (2016) 0.77

Mathematical Modelling of Molecular Pathways Enabling Tumour Cell Invasion and Migration. PLoS Comput Biol (2015) 0.77

Inhibition of Lipolysis Ameliorates Diabetic Phenotype in a Mouse Model of Obstructive Sleep Apnea. Am J Respir Cell Mol Biol (2016) 0.77

Can RNAi-mediated hsp90α knockdown in combination with 17-AAG be a therapy for glioma? FEBS Open Bio (2013) 0.77

Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins. PLoS One (2011) 0.77

Okadaic acid induces Akt hyperphosphorylation and an oxidative stress-mediated cell death in serum starved SK-N-SH human neuroblastoma cells that are augmented by rapamycin. Neurosci Lett (2012) 0.77

Dynamic Modeling and Analysis of the Cross-Talk between Insulin/AKT and MAPK/ERK Signaling Pathways. PLoS One (2016) 0.76

PI-103 and Quercetin Attenuate PI3K-AKT Signaling Pathway in T- Cell Lymphoma Exposed to Hydrogen Peroxide. PLoS One (2016) 0.76

B-cell activating factor-receptor specific activation of tumor necrosis factor receptor associated factor 6 and the phosphatidyl inositol 3-kinase pathway in lymphoma B cells. Leuk Lymphoma (2014) 0.76

Unexpected severe consequences of Pikfyve deletion by aP2- or Aq-promoter-driven Cre expression for glucose homeostasis and mammary gland development. Physiol Rep (2016) 0.76

AKT-mediated regulation of polarization in differentiated human neutrophil-like HL-60 cells. Inflamm Res (2012) 0.76

Simvastatin induced neurite outgrowth unveils role of cell surface cholesterol and acetyl CoA carboxylase in SH-SY5Y cells. PLoS One (2013) 0.76

Pancreatic cancer stem cell markers and exosomes - the incentive push. World J Gastroenterol (2016) 0.76

GAPDH binds Akt to facilitate cargo transport in the early secretory pathway. Exp Cell Res (2016) 0.75

Modulation of VEGF receptor 2 signaling by protein phosphatases. Pharmacol Res (2016) 0.75

Nik-related kinase regulates trophoblast proliferation and placental development by modulating AKT phosphorylation. PLoS One (2017) 0.75

The Rho Guanine Nucleotide Exchange Factor DRhoGEF2 Is a Genetic Modifier of the PI3K Pathway in Drosophila. PLoS One (2016) 0.75

The Akt signaling pathway is required for tissue maintenance and regeneration in planarians. BMC Dev Biol (2016) 0.75

Inability to replete white adipose tissue during the recovery phase of sepsis is associated with increased autophagy, apoptosis and proteasome activity. Am J Physiol Regul Integr Comp Physiol (2017) 0.75

Phosphate-Induced Renal Fibrosis Requires the Prolyl Isomerase Pin1. PLoS One (2016) 0.75

The Human Papillomavirus 16 E7 Oncoprotein Attenuates AKT Signaling To Promote Internal Ribosome Entry Site-Dependent Translation and Expression of c-MYC. J Virol (2016) 0.75

The Interplay Between Calmodulin and Membrane Interactions with the Pleckstrin Homology Domain of Akt. J Biol Chem (2016) 0.75

Long-time treatment by low-dose N-acetyl-L-cysteine enhances proinflammatory cytokine expressions in LPS-stimulated macrophages. PLoS One (2014) 0.75

Human Dynactin-Associated Protein Transforms NIH3T3 Cells to Generate Highly Vascularized Tumors with Weak Cell-Cell Interaction. PLoS One (2015) 0.75

Non-canonical Activation of Akt in Serum-Stimulated Fibroblasts, Revealed by Comparative Modeling of Pathway Dynamics. PLoS Comput Biol (2015) 0.75

Threonine 34 phosphorylation by phosphoinositide-dependent protein kinase 1 facilitates dissociation of Akt from the plasma membrane. Int J Biochem Cell Biol (2015) 0.75

Effect of Paullinia cupana Mart. Commercial Extract During the Aging of Middle Age Wistar Rats: Differential Effects on the Hippocampus and Striatum. Neurochem Res (2017) 0.75

UCHL1 promotes invasion of breast cancer cells through activating Akt signaling pathway. J Cell Biochem (2017) 0.75

T Cells Deficient in the Tyrosine Phosphatase SHP-1 Resist Suppression by Regulatory T Cells. J Immunol (2017) 0.75

Adaptation to chronic continuous hypoxia potentiates Akt/HK2 anti-apoptotic pathway during brief myocardial ischemia/reperfusion insult. Mol Cell Biochem (2017) 0.75

RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression. Cancer Res (2017) 0.75

Life in the fat lane: seasonal regulation of insulin sensitivity, food intake, and adipose biology in brown bears. J Comp Physiol B (2016) 0.75

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99

AKT/PKB signaling: navigating downstream. Cell (2007) 31.26

The phosphoinositide 3-kinase pathway. Science (2002) 24.72

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36

Cell signaling by receptor tyrosine kinases. Cell (2000) 18.16

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19

Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J (1996) 16.68

Oncogenic kinase signalling. Nature (2001) 16.30

mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48

Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89

SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell (2006) 10.50

PI3K pathway alterations in cancer: variations on a theme. Oncogene (2008) 9.94

PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell (2005) 8.22

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer (2006) 7.53

Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J (2008) 7.18

Perturbations of the AKT signaling pathway in human cancer. Oncogene (2005) 6.64

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62

A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61

Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J (1998) 6.28

A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A (2001) 6.25

The two TORCs and Akt. Dev Cell (2007) 6.17

Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer (2005) 6.05

PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell (2007) 6.00

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell (2009) 5.97

HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol (2001) 5.82

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem (2005) 5.62

PI3K/Akt signalling pathway and cancer. Cancer Treat Rev (2004) 5.46

The Akt-mTOR tango and its relevance to cancer. Cancer Cell (2005) 5.34

Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell (2006) 5.19

PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol (2004) 5.10

mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol (2006) 5.06

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J (2008) 4.79

Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev (2006) 4.78

Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res (2005) 4.74

The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res (1999) 4.66

Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J (2003) 4.65

Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A (2000) 4.55

Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature (2007) 4.54

The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J (2008) 4.49

AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem (1999) 4.49

The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol (2007) 4.49

A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37

Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell (2003) 4.37

Function of WW domains as phosphoserine- or phosphothreonine-binding modules. Science (1999) 4.36

Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene (1998) 4.31

From promiscuity to precision: protein phosphatases get a makeover. Mol Cell (2009) 4.17

Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochim Biophys Acta (2004) 4.11

Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell (2006) 3.83

SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene (2005) 3.77

Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2008) 3.74

Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68

Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol Cell (2002) 3.53

Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med (2002) 3.53

An expanding role for mTOR in cancer. Trends Mol Med (2005) 3.40

Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene (2006) 3.39

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets (2008) 3.36

PKB binding proteins. Getting in on the Akt. Cell (2002) 3.34

Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell (2003) 3.33

Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell (2003) 3.25

Alterations of the PPP2R1B gene in human lung and colon cancer. Science (1998) 3.14

Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J (2007) 3.08

PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci (2008) 3.04

The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature (2002) 3.02

Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem (2002) 3.01

TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res (2009) 2.96

PP2A: the expected tumor suppressor. Curr Opin Genet Dev (2005) 2.91

Cellular signaling: pivoting around PDK-1. Cell (2000) 2.86

GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77

Heat shock protein 90. Curr Opin Oncol (2003) 2.73

Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans (2007) 2.70

A new mutational AKTivation in the PI3K pathway. Cancer Cell (2007) 2.62

A PP2A regulatory subunit regulates C. elegans insulin/IGF-1 signaling by modulating AKT-1 phosphorylation. Cell (2009) 2.61

Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med (2008) 2.52

Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene (2002) 2.50

Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem (2007) 2.36

Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol (2004) 2.32

The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene (2007) 2.31

Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci U S A (2002) 2.28

XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res (2001) 2.25

The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem (2007) 2.24

c-Jun N-terminal kinases mediate reactivation of Akt and cardiomyocyte survival after hypoxic injury in vitro and in vivo. Circ Res (2005) 2.23

Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett (2003) 2.22

The proteasomal system. Mol Aspects Med (2009) 2.19

AKT signaling in normal and malignant cells. Oncogene (2005) 2.14

PP2A: unveiling a reluctant tumor suppressor. Cell (2007) 2.12

Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer (2006) 2.11

Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11

Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene (2000) 2.08

New insights into mTOR signaling: mTORC2 and beyond. Sci Signal (2009) 2.08

Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal (2009) 2.07

Involvement of PP2A in viral and cellular transformation. Oncogene (2005) 2.07

Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat Cell Biol (2005) 2.06

Physiological functions of protein kinase B/Akt. Biochem Soc Trans (2004) 2.00

PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol (2009) 2.00

Stabilization of Mdm2 via decreased ubiquitination is mediated by protein kinase B/Akt-dependent phosphorylation. J Biol Chem (2004) 1.95

PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab (2008) 1.92

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18

Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol (2004) 9.80

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12

IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell (2004) 6.13

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91

IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48

Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17

Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell (2008) 3.95

Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell (2005) 3.89

p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol (2011) 3.85

Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science (2005) 3.80

Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell (2005) 3.67

Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53

Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. Mol Cell (2007) 3.42

Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36

Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell (2013) 3.32

Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell (2008) 3.32

Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol (2007) 3.23

Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10

Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A (2002) 3.08

TRIM24 links a non-canonical histone signature to breast cancer. Nature (2010) 2.99

Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming. J Biol Chem (2010) 2.93

Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81

Improved peak detection and quantification of mass spectrometry data acquired from surface-enhanced laser desorption and ionization by denoising spectra with the undecimated discrete wavelet transform. Proteomics (2005) 2.81

EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature (2013) 2.67

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res (2004) 2.64

A new mutational AKTivation in the PI3K pathway. Cancer Cell (2007) 2.62

Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res (2005) 2.58

The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines. Breast Cancer (Auckl) (2010) 2.57

KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 2.55

EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54

Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell (2004) 2.53

Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res (2004) 2.50

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res (2004) 2.48

Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol (2006) 2.45

Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res (2004) 2.44

CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol (2010) 2.36

beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell (2002) 2.33

The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell (2012) 2.30

Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem (2007) 2.30

A new fork for clinical application: targeting forkhead transcription factors in cancer. Clin Cancer Res (2009) 2.27

LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med (2012) 2.24

Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol Cell Biol (2005) 2.20

The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell (2006) 2.13

Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem (2006) 2.11

Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res (2007) 2.10

14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell (2009) 2.09

Krüppel-like factor 8 induces epithelial to mesenchymal transition and epithelial cell invasion. Cancer Res (2007) 2.02

The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02

Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01

Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1. Cancer Res (2012) 1.97

Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer. J Natl Cancer Inst (2002) 1.95

EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat (2006) 1.92

GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell (2008) 1.91

Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization. Clin Chem (2003) 1.88

Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res (2008) 1.88

Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene (2007) 1.86

KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell (2009) 1.85

Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog (2006) 1.78

Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia (2011) 1.78

Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res (2004) 1.76

MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol (2006) 1.75

14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res (2009) 1.74

Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res (2009) 1.74

Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog (2009) 1.71

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell (2010) 1.71

RAC1 activation mediates Twist1-induced cancer cell migration. Nat Cell Biol (2012) 1.69

Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol (2009) 1.67

Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell (2002) 1.67

Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol (2009) 1.61

Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res (2002) 1.58

Wnt, hedgehog and snail: sister pathways that control by GSK-3beta and beta-Trcp in the regulation of metastasis. Cell Cycle (2005) 1.57

Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res (2008) 1.56

Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell (2012) 1.54

Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem (2011) 1.52

Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res (2005) 1.51

p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem (2009) 1.48

Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res (2009) 1.48

Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45

Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-β-dependent cancer metastasis. J Clin Invest (2014) 1.45

Galectin-3 mediates nuclear beta-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res (2009) 1.44

Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res (2006) 1.43

Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT. Mol Endocrinol (2010) 1.42

Biochemical isolation and characterization of the tubulovesicular LC3-positive autophagosomal compartment. J Biol Chem (2009) 1.41

A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase/Akt in HER2 overexpressing cells. Cancer Res (2005) 1.41

Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat Cell Biol (2011) 1.40

Crystal structure of the human FOXO3a-DBD/DNA complex suggests the effects of post-translational modification. Nucleic Acids Res (2007) 1.38

All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle (2007) 1.38

Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res (2008) 1.37

The translocon Sec61beta localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus. J Biol Chem (2010) 1.36

Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell (2007) 1.35

Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer. Am J Transl Res (2012) 1.33

Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem (2009) 1.32

IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression. Mol Cell (2011) 1.32

Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther (2004) 1.32

Crossregulation of NF-kappaB by the APC/GSK-3beta/beta-catenin pathway. Mol Carcinog (2004) 1.31